



6<sup>th</sup> July 2020

**Incanthera plc**

**("Incanthera" or the "Company")**

### **Grant of options**

Incanthera plc announces that it has adopted both an approved and unapproved share option scheme (the "Schemes") and, on 4<sup>th</sup> July 2020, made a grant of options under both Schemes to directors and others.

#### **Option Schemes and Grant of Options**

As outlined in the Company's Admission Document of February this year, the Company has adopted the Schemes to incentivise management performance for the benefit of all shareholders by way of options which are subject to time and performance conditions.

For the purposes of the Schemes, a maximum of 10 per cent. of the Company's issued share capital in aggregate, from time to time, may be issued without the prior approval of shareholders of the Company. The exercise period for options granted under the Schemes is three years from the date of grant.

Vesting criteria for options granted under the Schemes are subject to time and performance conditions as follows:

<b>Amount Vesting</b>	<b>Time Condition</b>
36 per cent. ("Tranche One")	On the first anniversary of the date of the grant
32 per cent. ("Tranche two")	On the second anniversary of the date of the grant
32 per cent. ("Tranche three")	On the third anniversary of the date of the grant

**Performance Condition:** Entering into a commercial agreement relating to its intellectual property.

The Schemes provide for good/bad leaver provisions and other standard terms normally associated with such schemes.

The Company has granted the following options under the Scheme:

<b>Option holder (scheme)</b>	<b>Number of Options granted</b>	<b>Exercise Price</b>	<b>Options Granted as Percentage of Issued Share Capital on Admission</b>
Tim McCarthy (Approved)	1,100,000	9.5p	1.8%
Simon Ward (Approved)	1,100,000	9.5p	1.8%
Pawel Zolnierczyk (Approved)	1,100,000	9.5p	1.8%
Suzanne Brocks (Approved)	1,100,000	9.5p	1.8%
Laura Brogden (Unapproved)	1,100,000	9.5p	1.8%

Kevin Hammond (Unapproved)	275,000	9.5p	0.5%
Total	5,775,000		9.5%

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

The directors of the Company take responsibility for this announcement.

**For further information, please contact:**

**Incanthera plc**

[www.incanthera.com](http://www.incanthera.com)

**Tim McCarthy, Chairman**

[tim.mccarthy@incanthera.com](mailto:tim.mccarthy@incanthera.com)

**+44 (0) 7831 675747**

**Simon Ward, Chief Executive Officer**

[simon.ward@incanthera.com](mailto:simon.ward@incanthera.com)

**+44 (0) 7747 625506**

**Suzanne Brocks, Head of Communications**

[suzanne.brocks@incanthera.com](mailto:suzanne.brocks@incanthera.com)

**+44 (0) 7776 234600**

**AQSE Corporate Adviser:**

**Cairn Financial Advisers LLP**

Jo Turner / James Lewis

**+44 (0) 20 7213 0880**

**Broker:**

**Stanford Capital Partners Ltd**

Patrick Claridge / John Howes / Bob Pountney

**+44 (0) 20 3815 888**

**Notification and public disclosure of transactions by persons discharging managerial responsibilities/ person closely associated with them.**

<b>1.</b>	<b>Details of the person discharging managerial responsibilities/person closely associated</b>											
	Name	<table> <tr> <td>1. Tim McCarthy</td> <td>Chairman</td> </tr> <tr> <td>2. Simon Ward</td> <td>CEO</td> </tr> <tr> <td>3. Pawel Zolnierczyk</td> <td>PDMR</td> </tr> <tr> <td>4. Suzanne Brocks</td> <td>PDMR</td> </tr> <tr> <td>5. Laura Brogden</td> <td>PDMR</td> </tr> </table>	1. Tim McCarthy	Chairman	2. Simon Ward	CEO	3. Pawel Zolnierczyk	PDMR	4. Suzanne Brocks	PDMR	5. Laura Brogden	PDMR
1. Tim McCarthy	Chairman											
2. Simon Ward	CEO											
3. Pawel Zolnierczyk	PDMR											
4. Suzanne Brocks	PDMR											
5. Laura Brogden	PDMR											
<b>2.</b>	<b>Reason for the notification</b>											
a)	Position/status	As above										
b)	Initial notification/Amendment	Initial Notification										
<b>3.</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>											
a)	Name	Incanthera plc										
b)	LEI	2138002HEV4UFBOEXQ97										
<b>4.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>											

a)	Description of the financial instrument	Options																						
b)	Identification code	GB00BGL7YW15																						
c)	Nature of the transactions	Grant of Options																						
d)	Volumes and Prices	<table border="1"> <thead> <tr> <th></th> <th>Volume</th> <th>Price</th> </tr> </thead> <tbody> <tr> <td>1.</td> <td>1,100,000</td> <td>9.5p</td> </tr> <tr> <td>2.</td> <td>1,100,000</td> <td>9.5p</td> </tr> <tr> <td>3.</td> <td>1,100,000</td> <td>9.5p</td> </tr> <tr> <td>4.</td> <td>1,100,000</td> <td>9.5p</td> </tr> <tr> <td>5.</td> <td>1,100,000</td> <td>9.5p</td> </tr> <tr> <td></td> <td></td> <td></td> </tr> </tbody> </table>			Volume	Price	1.	1,100,000	9.5p	2.	1,100,000	9.5p	3.	1,100,000	9.5p	4.	1,100,000	9.5p	5.	1,100,000	9.5p			
	Volume	Price																						
1.	1,100,000	9.5p																						
2.	1,100,000	9.5p																						
3.	1,100,000	9.5p																						
4.	1,100,000	9.5p																						
5.	1,100,000	9.5p																						
e)	Aggregated information - Aggregated volume - Price	<table border="1"> <thead> <tr> <th>Volume</th> <th>Prices</th> </tr> </thead> <tbody> <tr> <td>5,500,000</td> <td>9.5p</td> </tr> </tbody> </table>		Volume	Prices	5,500,000	9.5p																	
Volume	Prices																							
5,500,000	9.5p																							
f)	Date of the transactions	4 <sup>th</sup> July 2020																						
f)	Place of the transactions	AQSE Growth Market, UK																						

### Notes to Editors

Incanthera is a specialist oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions.

The Company's current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. This has achieved proof of concept and the Company is now focussed upon delivering Sol to a commercial partner.

The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford and has acquired and developed a portfolio of specific cancer-targeting therapeutics through a Pipeline Agreement with the ICT and other corporate acquisitions.

Incanthera's strategy is to develop each candidate in the portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

For more information on the Company please visit: [www.incanthera.com](http://www.incanthera.com)